Pfizer Q2: Dividends Speak Louder Than EPS

Group 1 - The article discusses Pfizer Inc. stock and its performance in relation to the Trump administration's drug pricing plan [1] - The author previously expressed a preference for AbbVie over Pfizer in the context of dividend checks [1] Group 2 - The service mentioned claims to help members outperform the S&P 500 and avoid significant losses during market volatility [2] - The method offered is presented as a proven strategy for investment success [2]